Navigation Links
Mode Of Action Of The Anti-Convulsant Valproate

Researchers from Australia have recently shown, using a yeast-based in vitro bioassay for steroid hormones that valproate, a commonly used anti-convulsant for the treatment of epilepsy and bipolar disorder, is an anti-androgen and anti-progestin. //

Anti-convulsant treatment is associated with a high prevalence of reproductive dysfunction compared with age-matched non-epileptics.

The researchers examined the widely used anti-convulsants valproate (VPA) and carbamazepine (CBZ) for steroidal bioactivity using a yeast-based steroid receptor-a-galactosidase reporter assay for the androgen receptor (AR), progesterone receptor (PR) or estrogen receptor (ER).

Bioassays were performed to detect agonist activity by exposing yeast to CBZ or valproate or to detect antagonist activity by exposing yeast stimulated with testosterone, progesterone or estradiol together with either valproate or CBZ for 4 (PR) or 16 (AR, ER) hours. Valproate showed dose-dependent inhibition of progesterone-induced PR- and testosterone-induced AR activity but had no ER antagonist bioactivity and no significant PR, AR or ER agonist bioactivity.

Valproate also showed a dose-dependent blockade of DHT's suppression of AR-mediated NF-êB activation in human mammalian cells.

By contrast, CBZ had no significant PR, AR or ER agonist or AR and ER antagonist bioactivity but at the highest concentration tested it did antagonize PR activity.

The authors writing in the journal Steroids (available online 13 September 2005) conclude that valproate is a non-steroidal antagonist for human AR and PR but not ER. Valproate’s androgen and progesterone antagonism at concentrations within therapeutic blood levels seems likely to contribute to the frequency of reproductive endocrine disturbances among patients treated with valproate.
'"/>




Page: 1

Related medicine news :

1. Action of nerve cells
2. Herbs With Estrogen Action Aggravate Cancer Risk
3. Immunosuppressive Action Of Fungal Metabolite - Gliotoxin
4. Legal Action against Authority Regarding Outbreak of Legionnaires’ Diseas
5. Action Plan Against Drug Deaths Launched
6. Ramadoss to Take Severe Action against Fertility Clinics Conducting Stem Cell Therapy
7. UN Formulates Action Plan for Relief to Recovery in Quake-hit Areas of Pakistan
8. HIV Infected Body Parts Stolen: Biomedical Tissue Services To Face Legal Action
9. India to Implement National Action Plan against TB-HIV
10. Action Urged Against Fake Medicines
11. Supreme Court Warns Medicos of Contempt Action
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several ... had left education officials with a number of critical issues to address before students ... to be accomplished with little or no disruption to class schedules. Second, the project ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success depends ... instruments for research and understanding the basic principles that were designed to drive ... innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories working ...
(Date:5/24/2017)... ... 24, 2017 , ... Altec Products, Inc., a leader in enterprise ... one-day technology conference in San Diego, CA. , At nVerge 2017, Altec will ... utilize and enhance their Sage ERP solutions by providing improved visibility and control to ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. ... NY, who have now spent 10 years as clinical instructors for the reputable ... College of Dentistry. Through the program, private practitioners receive cutting-edge clinical training and ...
(Date:5/24/2017)... ... , ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® ... for a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice that ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
Breaking Medicine Technology: